The US Food and Drug Administration has seized thousands of units of counterfeit Ozempic,
The regulator advised wholesalers, retail pharmacies, health care practitioners and patients to check the product they have received and not distribute or sell products labeled with lot number NAR0074 and serial number 430834149057.
The FDA and Novo are testing the seized products and don’t yet have information about the drugs’ identity, quality, or safety.
Demand for Ozempic has soared as people turn to a new range ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.